Cargando…

Cellular Therapies in Pediatric Liver Diseases

Liver transplantation is the gold standard for the treatment of pediatric end-stage liver disease and liver based metabolic disorders. Although liver transplant is successful, its wider application is limited by shortage of donor organs, surgical complications, need for life long immunosuppressive m...

Descripción completa

Detalles Bibliográficos
Autores principales: Vimalesvaran, Sunitha, Nulty, Jessica, Dhawan, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406752/
https://www.ncbi.nlm.nih.gov/pubmed/36010561
http://dx.doi.org/10.3390/cells11162483
_version_ 1784774198014509056
author Vimalesvaran, Sunitha
Nulty, Jessica
Dhawan, Anil
author_facet Vimalesvaran, Sunitha
Nulty, Jessica
Dhawan, Anil
author_sort Vimalesvaran, Sunitha
collection PubMed
description Liver transplantation is the gold standard for the treatment of pediatric end-stage liver disease and liver based metabolic disorders. Although liver transplant is successful, its wider application is limited by shortage of donor organs, surgical complications, need for life long immunosuppressive medication and its associated complications. Cellular therapies such as hepatocytes and mesenchymal stromal cells (MSCs) are currently emerging as an attractive alternative to liver transplantation. The aim of this review is to present the existing world experience in hepatocyte and MSC transplantation and the potential for future effective applications of these modalities of treatment.
format Online
Article
Text
id pubmed-9406752
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94067522022-08-26 Cellular Therapies in Pediatric Liver Diseases Vimalesvaran, Sunitha Nulty, Jessica Dhawan, Anil Cells Review Liver transplantation is the gold standard for the treatment of pediatric end-stage liver disease and liver based metabolic disorders. Although liver transplant is successful, its wider application is limited by shortage of donor organs, surgical complications, need for life long immunosuppressive medication and its associated complications. Cellular therapies such as hepatocytes and mesenchymal stromal cells (MSCs) are currently emerging as an attractive alternative to liver transplantation. The aim of this review is to present the existing world experience in hepatocyte and MSC transplantation and the potential for future effective applications of these modalities of treatment. MDPI 2022-08-10 /pmc/articles/PMC9406752/ /pubmed/36010561 http://dx.doi.org/10.3390/cells11162483 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vimalesvaran, Sunitha
Nulty, Jessica
Dhawan, Anil
Cellular Therapies in Pediatric Liver Diseases
title Cellular Therapies in Pediatric Liver Diseases
title_full Cellular Therapies in Pediatric Liver Diseases
title_fullStr Cellular Therapies in Pediatric Liver Diseases
title_full_unstemmed Cellular Therapies in Pediatric Liver Diseases
title_short Cellular Therapies in Pediatric Liver Diseases
title_sort cellular therapies in pediatric liver diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406752/
https://www.ncbi.nlm.nih.gov/pubmed/36010561
http://dx.doi.org/10.3390/cells11162483
work_keys_str_mv AT vimalesvaransunitha cellulartherapiesinpediatricliverdiseases
AT nultyjessica cellulartherapiesinpediatricliverdiseases
AT dhawananil cellulartherapiesinpediatricliverdiseases